Discover more from FarmaKology’s Substack
FarmaKology-Scientists created new antibody to combat breast cancer
Would you like to submit an article, some interesting news, or get your startup featured? Send whatever you have to "email@example.com", and happy to have you featured on our newsletter+21K Subs.
Krystal Biotech, Inc.
Krystal Biotech, Inc., our mission is to make a meaningful difference in the lives of underserved patient populations suffering from debilitating skin diseases. We work to accomplish this goal through scientific innovation and operational excellence, believing that "nature operates in the shortest way possible" (Aristotle). The diseases for which we develop therapies provide inspiration for our day-to-day activities. There is clarity in purpose, a collective empathy driving us forward. Krystal was named after this clarity — a simple realization that we can do better. In doing so, we extend gratitude to the patients, caregivers, advocates and physicians dedicated to the diseases which unite us in purpose.
Cassava Sciences Completes Enrollment for Pivotal Phase 3 Program of Simufilam in Alzheimer’s Disease
Cassava Sciences, Inc. , a biotechnology company, today announced the completion of patient enrollment in a pair of Phase 3 trials to evaluate the safety and efficacy of oral simufilam versus placebo in Alzheimer's disease dementia. Simufilam is Cassava Sciences’ proprietary oral drug candidate. This investigational drug binds to altered filamin A protein in the brain and restores its normal shape and function. By targeting altered filamin A, simufilam may help patients with Alzheimer’s achieve better health outcomes.
Toragen, Inc. Announced Positive Safety Update from Cohort 1 of its Phase 1 Trial in Patients with Human Papillomavirus-Induced Cancer
Toragen Inc., a San Diego-based clinical-stage biotechnology company focused on developing uniquely selective drugs targeting cancers caused by viruses, announced positive safety data from Cohort 1 of its Phase 1 trial of TGN-S11, its first drug candidate, in patients with HPV-associated cancers.
ExactCare and Tabula Rasa to Combine, Creating a Leading, Independent Pharmacy Care Management Company for Patients with the Most Complex Needs
ExactCare®, a national provider of medication management and comprehensive long-term pharmacy services and a Nautic Partners portfolio company, today announced that the acquisition of Tabula Rasa HealthCare, Inc.®, a leading healthcare company advancing personalized, comprehensive care for value-based care organizations, is complete.
New asundexian Phase III study to include patients with atrial fibrillation ineligible for oral anticoagulant treatment
Bayer expands its Phase III OCEANIC clinical development program for the investigational drug asundexian by initiating a third clinical study, OCEANIC-AFINA. OCEANIC AFINA is a Phase III study investigating asundexian as a potential treatment in patients (≥65 years of age) with atrial fibrillation at high risk for stroke or systemic embolism who are deemed ineligible for oral anticoagulation treatment due to an increased risk of bleeding. OCEANIC-AFINA complements OCEANIC-AF, an ongoing Phase III study investigating the efficacy and safety of asundexian for the prevention of stroke or systemic embolism in people with AF at risk of stroke. Together, the results from OCEANIC-AFINA and OCEANIC-AF aim at providing robust evidence for the efficacy and safety of asundexian across a broad range of patients with AF, including those who are at high risk for both ischemic stroke or systemic embolism and major bleeding events.